News Lipigon Pharmaceuticals AB

Equities

LPGO

SE0015382072

Market Closed - Nasdaq Stockholm Other stock markets 11:16:26 2024-04-19 am EDT			5-day change	1st Jan Change
0.339 ^SEK	+16.90%		+11.15%	-21.35%

Feb. 22	Lipigon Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
Feb. 07	Lipigon Pharmaceuticals’ Lipisense Gets Swedish Regulators' Nod for Mid-stage Study	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lipigon Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 22	CI
Lipigon Pharmaceuticals’ Lipisense Gets Swedish Regulators' Nod for Mid-stage Study	Feb. 07	MT
The Swedish Medical Products Agency Approves Lipigon's Phase II Study with Lipisense	Feb. 07	CI
Lipigon Pharmaceuticals AB Announces Lipisense Progressing to Phase II Trials	Dec. 12	CI
Lipigon Pharmaceuticals AB Reports A Statically Confirms reduction of target protein ANGPTL4 after repeate treatment with Lipisense ®	Nov. 23	CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 23	CI
Lipigon Applies for Clinical Trial Phase II for Lipisense	Nov. 13	CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29	CI
Lipigon Pharmaceuticals AB Announces Positive Safety Results and Encouraging Target Engagement Data from the Phase I Lipisense Trial	23-07-12	CI
Lipigon Pharmaceuticals Surges 40% on Lipisense Development, Licensing Deal in China	23-06-27	MT
Lipigon Announces Development and License Agreement with Leaderna Therapeutics Ltd	23-06-27	CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-28	CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
Lipigon Announces Further Positive Data from Phase I Trial of Lipisense	23-01-19	CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-24	CI
Lipigon Pharmaceuticals AB Announces Positive Top-Line Data from Phase I Clinical Study of Lipisense	22-10-05	CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-30	CI
Lipigon Pharmaceuticals AB Announces Liver-Specific Treatment of Target Protein ANGPTL4 Is Effective and Safe	22-06-09	CI
Lipigon Pharmaceuticals AB Announces First-In-Human Phase I Trial with Lipigon's Lipid-Lowering Candidate Lipisense	22-05-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Lipigon Pharmaceuticals AB

Equities

LPGO

SE0015382072

Summary

Filters